AstraZeneca has struck a deal with Donald Trump to lower drug prices by offering discounts on certain medicines to the Medicaid health plan. This agreement is significant as it aims to make prescription medications more affordable for Americans while also addressing tariff concerns from the administration. Such initiatives could lead to broader discussions on healthcare affordability and the role of pharmaceutical companies in the U.S.

In a significant development, President Trump announced a new prescription drug deal with pharmaceutical giant AstraZeneca, crediting his 100-percent tariff threat as a key factor in making the agreement possible. This deal is expected to lower drug prices for Americans, showcasing the administration's commitment to addressing healthcare costs. It highlights the ongoing efforts to negotiate better terms with pharmaceutical companies, which could have a lasting impact on the industry and consumers alike.